These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 38061767)
1. Factors associated with mental illness in patients with rheumatoid arthritis initiating b/ts DMARDs: A population-based study. Chen HH; Wu PY; Lin CH; Wu CL; Chao WC Int J Rheum Dis; 2024 Jan; 27(1):e14992. PubMed ID: 38061767 [TBL] [Abstract][Full Text] [Related]
2. Incidence of dementia in patients with rheumatoid arthritis and association with disease modifying anti-rheumatic drugs - Analysis of a national claims database. Sattui SE; Navarro-Millan I; Xie F; Rajan M; Yun H; Curtis JR Semin Arthritis Rheum; 2022 Dec; 57():152083. PubMed ID: 36155968 [TBL] [Abstract][Full Text] [Related]
3. HBV reactivation in HBsAg-/HBcAb+ rheumatoid arthritis patients receiving biologic/targeted synthetic DMARDs. Kuo MH; Tseng CW; Ko PH; Wang ST; Lu MC; Tung CH; Tseng KC; Huang KY; Lee CH; Lai NS Liver Int; 2024 Feb; 44(2):497-507. PubMed ID: 38010984 [TBL] [Abstract][Full Text] [Related]
4. Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study. Simon TA; Boers M; Hochberg M; Baker N; Skovron ML; Ray N; Singhal S; Suissa S; Gomez-Caminero A Arthritis Res Ther; 2019 Nov; 21(1):228. PubMed ID: 31703717 [TBL] [Abstract][Full Text] [Related]
5. Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice. Huss V; Bower H; Wadström H; Frisell T; Askling J; Rheumatology (Oxford); 2022 May; 61(5):1810-1818. PubMed ID: 34324640 [TBL] [Abstract][Full Text] [Related]
6. Incident and recurrent herpes zoster for first-line bDMARD and tsDMARD users in seropositive rheumatoid arthritis patients: a nationwide cohort study. Jeong S; Choi S; Park SM; Kim J; Ghang B; Lee EY Arthritis Res Ther; 2022 Jul; 24(1):180. PubMed ID: 35902964 [TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study. Pappas DA; St John G; Etzel CJ; Fiore S; Blachley T; Kimura T; Punekar R; Emeanuru K; Choi J; Boklage S; Kremer JM Ann Rheum Dis; 2021 Jan; 80(1):96-102. PubMed ID: 32719038 [TBL] [Abstract][Full Text] [Related]
8. Incidence of Interstitial Lung Disease in Patients With Rheumatoid Arthritis Treated With Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs. Baker MC; Liu Y; Lu R; Lin J; Melehani J; Robinson WH JAMA Netw Open; 2023 Mar; 6(3):e233640. PubMed ID: 36939701 [TBL] [Abstract][Full Text] [Related]
9. Changes in Market Share of Biologic and Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs for Treatment of Rheumatoid Arthritis: Results from the Ontario Best-Practice Research Initiative Database. Hepworth E; Movahedi M; Rampakakis E; Mirza R; Lau A; Cesta A; Pope J; Sampalis JS; Bombardier C Curr Rheumatol Rev; 2021; 17(3):349-359. PubMed ID: 33308132 [TBL] [Abstract][Full Text] [Related]
10. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden. Wadström H; Frisell T; Askling J; JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211 [TBL] [Abstract][Full Text] [Related]
11. Singapore Chapter of Rheumatologists updated consensus statement on the eligibility for government subsidization of biologic and targeted-synthetic therapy for the treatment of rheumatoid arthritis. Leong JWY; Cheung PP; Dissanayake S; Fong WWS; Leong KH; Leung YY; Lim AYN; Lui NL; Manghani M; Santosa A; Sriranganathan MK; Suresh E; Tan TC; Teng GG; Lahiri M Int J Rheum Dis; 2020 Feb; 23(2):140-152. PubMed ID: 31859424 [TBL] [Abstract][Full Text] [Related]
12. Comparative risk of osteoporotic fracture among patients with rheumatoid arthritis receiving TNF inhibitors versus other biologics: a cohort study. Shin A; Park EH; Dong YH; Ha YJ; Lee YJ; Lee EB; Song YW; Kang EH Osteoporos Int; 2020 Nov; 31(11):2131-2139. PubMed ID: 32514765 [TBL] [Abstract][Full Text] [Related]
13. Incidence of inpatient venous thromboembolism in treated patients with rheumatoid arthritis and the association with switching biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in the real-world setting. Liang H; Danwada R; Guo D; Curtis JR; Kilpatrick RD; Hendrickson B; Islam SS RMD Open; 2019; 5(2):e001013. PubMed ID: 31673413 [TBL] [Abstract][Full Text] [Related]
14. Four-year follow-up of atherogenicity in rheumatoid arthritis patients: from the nationwide Korean College of Rheumatology Biologics Registry. Min HK; Kim HR; Lee SH; Shin K; Kim HA; Park SH; Kwok SK Clin Rheumatol; 2021 Aug; 40(8):3105-3113. PubMed ID: 33576925 [TBL] [Abstract][Full Text] [Related]
15. Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland. Finckh A; Tellenbach C; Herzog L; Scherer A; Moeller B; Ciurea A; von Muehlenen I; Gabay C; Kyburz D; Brulhart L; Müller R; Hasler P; Zufferey P; RMD Open; 2020 May; 6(1):. PubMed ID: 32385143 [TBL] [Abstract][Full Text] [Related]
16. Real-world Comparative Effectiveness of Methotrexate-based Combinations for Rheumatoid Arthritis: A Retrospective Cohort Study. Huang Y; Agarwal SK; Chen H; Chatterjee S; Johnson ML; Aparasu RR Clin Ther; 2023 Sep; 45(9):e177-e186. PubMed ID: 37573225 [TBL] [Abstract][Full Text] [Related]
17. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT. Brown S; Everett CC; Naraghi K; Davies C; Dawkins B; Hulme C; McCabe C; Pavitt S; Emery P; Sharples L; Buch MH Health Technol Assess; 2018 Jun; 22(34):1-280. PubMed ID: 29900829 [TBL] [Abstract][Full Text] [Related]
18. Association of first, second, and third-line bDMARDs and tsDMARD with drug survival among seropositive rheumatoid arthritis patients: Cohort study in A real world setting. Choi S; Ghang B; Jeong S; Choi D; Lee JS; Park SM; Lee EY Semin Arthritis Rheum; 2021 Aug; 51(4):685-691. PubMed ID: 34139521 [TBL] [Abstract][Full Text] [Related]
19. Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics. Frisell T; Baecklund E; Bengtsson K; Di Giuseppe D; Forsblad-d'Elia H; Askling J; Ann Rheum Dis; 2018 May; 77(5):650-657. PubMed ID: 29237621 [TBL] [Abstract][Full Text] [Related]
20. Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis. Das P; Weisenfeld D; Dahal K; De D; Feathers V; Coblyn JS; Weinblatt ME; Shadick NA; Cai T; Liao KP Arthritis Res Ther; 2023 Jun; 25(1):93. PubMed ID: 37269020 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]